oral ROR_ nuclear receptor agonist

450 mg BID, phase I/II, cancer

from change in MoA of ROR_ antagonist + opt.

Journal of Medicinal Chemistry


Chemical structure of molecule LYC-55716 Cintirorgon

The Lycera ROR gamma agonist, cintirorgon (LYC-55716), is a first-in-class phase 1b clinical candidate for cancer immunotherapy (in combination with pembrolizumab in NSCLC). ROR gamma antagonists have been extensively…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: